Translocation of lysophosphatidic acid phosphatase in response to gonadotropin-releasing hormone to the plasma membrane in ovarian cancer cell

Wen Shu Sun, Atsushi Imai, Michiyo Sugiyama, Tatsuro Furui, Teruhiko Tamaya, Masanao Saio, Andrew J. Morris

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objective Lysophosphatidic acid mediates proliferative and/or morphologic effects on multiple cell lineages, which include ovarian cancer cells. Lysophosphatidic acid hydrolysis limits the duration of lysophosphatidic acid's action. We examined hormonal translocation of lipid phosphate phosphatase type 3 to the plasma membrane in gonadotropin-releasing hormone-responsive ovarian cancers. Study design Ovarian cancers that were removed surgically and the ovarian cancer cell lines Caov-3 and SK-OV-3 were examined. Lipid phosphate phosphatase type 3 protein and activity in plasma membranes were assessed by immunohistochemical staining with lipid phosphate phosphatase type 3-specific antibodies and by the measurement of the conversion of exogenous [ 3H-oleoyl]lysophosphatidic acid to mono[ 3H-oleoyl] glycerol, respectively. Results In ovarian cancers that were removed surgically, the cell surface staining and activity measurements indicated that a portion of the enzyme was localized to the plasma membrane. In Caov-3 cells and SK-OV-3 cells, lipid phosphate phosphatase type 3 protein was present both in the cytoplasm and at the plasma membrane. Treatment of the cells with a gonadotropin-releasing hormone agonist buserelin produced a rapid and progressive translocation of lipid phosphate phosphatase type 3 protein to the plasma membrane, with a concomitant loss of cytoplasmic staining. The enzyme activity in plasma membrane was also increased when the cell lines were exposed to the gonadotropin-releasing hormone agonist in intact cells before the assay of the cell membranes. Conclusion These findings support the presence of lipid phosphate phosphatase type 3 in plasma membrane of ovarian cancers and provide for the ability of agonists (such as gonadotropin-releasing hormone) to induce the translocation of lipid phosphate phosphatase type 3 to plasma membrane in ovarian cancer cells.

Original languageEnglish
Pages (from-to)143-149
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume191
Issue number1
DOIs
StatePublished - Jul 2004

Bibliographical note

Funding Information:
Supported in part by research grants (#12470340 and #14770844) from the Ministry of Education, Culture and Science, Japan.

Funding

Supported in part by research grants (#12470340 and #14770844) from the Ministry of Education, Culture and Science, Japan.

FundersFunder number
Ministerie van Onderwijs, Cultuur en Wetenschap

    Keywords

    • Antiproliferative action
    • Gonadotropin-releasing hormone
    • Lysophosphatidic acid
    • Ovarian cancer
    • Phosphatase

    ASJC Scopus subject areas

    • Obstetrics and Gynecology

    Fingerprint

    Dive into the research topics of 'Translocation of lysophosphatidic acid phosphatase in response to gonadotropin-releasing hormone to the plasma membrane in ovarian cancer cell'. Together they form a unique fingerprint.

    Cite this